1 / 31

DRUG THERAPY OF AIRFLOW OBSTRUCTION PROFESSOR B J LIPWORTH Preventers (anti-inflammatory) Relievers (bronchodilators)

DRUG THERAPY OF AIRFLOW OBSTRUCTION PROFESSOR B J LIPWORTH Preventers (anti-inflammatory) Relievers (bronchodilators). THE INFLAMMATORY CASCADE Genetic predisposition + Trigger factor • Avoidance (e.g. viral, allergen, chemicals)

velika
Download Presentation

DRUG THERAPY OF AIRFLOW OBSTRUCTION PROFESSOR B J LIPWORTH Preventers (anti-inflammatory) Relievers (bronchodilators)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. DRUG THERAPY OF AIRFLOW OBSTRUCTION • PROFESSOR B J LIPWORTH • Preventers (anti-inflammatory) • Relievers (bronchodilators)

  2. THE INFLAMMATORY CASCADE Genetic predisposition + Trigger factor • Avoidance (e.g. viral, allergen, chemicals) Airway inflammation • Anti-inflammatory - corticosteroid Mediators • Anti-leukotriene (e.g. histamine, leukotriene) Anti-histamine Twitchy smooth muscle • Bronchodilators (Hyper-reactivity) - 2-agonists

  3. THE ASTHMA TREATMENT PYRAMID Oral Steroid ControllerTheophylline (Additive to ICS ) Leukotriene-antagonist Increasing Long-acting 2-agonist severity PreventerInhaled steroid ( Cromogylcate ?) RelieverShort-acting2-agonist PRN

  4. mild persistent moderate persistent severe persistent intermittent BTS Asthma Guidelines Step 4 Step 3 Step 2 Step 1 Short-acting ß2 agonists prn Inhaled steroids Add on LABA Add on LTRA/Theo

  5. ANTI-INFLAMMATORY: CORTICOSTEROIDS • Used in asthma and COPD • Oral steroid (prednisolone) - low therapeutic ratio • - only used for acute exacerbations • Inhaled steroid (beclomethasone) - higher therapeutic ratio • - used for maintenance therapy • Optimise lung delivery - large volume spacer

  6. Lung deposition of HFA-BDP, fluticasone and CFC-BDP MMAD = 1.1 µm MMAD = 2.5 µm MMAD = 3.5 µm

  7. Actions of a spacer device • Avoids coordination problems with pMDI • Reduces oropharyngeal and laryngeal side effects • Reduces systemic absorption from swallowed fraction • Acts a holding chamber for aerosol • Reduces particle size and velocity • Improves lung deposition

  8. ANTI-INFLAMMATORY: CROMONES • Only used in asthma (eg Cromoglycate) • Mast cell stabiliser - weak anti-inflammatory cf steroids • Cromoglycate effective in atopic children (exercise asthma) • Inhaled route only (compliance with QID dosing ) • No longer used due to poor efficacy

  9. ANTI-INFLAMMATORY: LEUKOTRIENE RECEPTOR ANTAGONISTS • Only used in asthma: bronchodilator + anti-inflammatory • Montelukast - oral route,once daily, high therapeutic ratio • Less potent anti-inflammatory than inhaled steroid • 2nd line: complimenatary non steroidal ant-inflammatory additive to inhaled steroid • Effective in exercise induced asthma • Also effective in allergic rhinitis ( with anti-histamine )

  10. ANTI-INFLAMMATORY: ANTIHISTAMINES • H1 receptor antagonists • Oral route • Only of value when known allergenic trigger (e.g. HDM ,pollen or cat) -ie in atopic asthma • 1st generation :Chlorpheniramine-sedative • 2nd generation: Cetirizine,Loratadine-non sedative • 3rd generation: Levocetirizine,Desloratadine - non sedative • More effective in allergic rhinitis than asthma • Additive effects when given together with leukotreine antagonist

  11. ANTI-INFLMMATORY Anti-IgE • Anti-IgE monoclonal antibody : Omalizumab (Xolair) • Omalizumab inhibits the binding to the high-affinity IgE receptor and inhibit mediator release from basophils and mast cells . • Injection every 2-4 weeks . • For patients with severe persistent allergic asthma despite max therapy –ie step 5 . • Very expensive . • No effect on pulmonary function but reduces exacerbations .

  12. BRONCHODILATORS: 2-AGONISTS • Stimulate bronchial smooth muscle 2-receptors:  cAMP • Short-acting - salbutamol • Long-acting – salmeterol / formoterol • Combination inhalers-eg Seretide / Symbicort • Used in asthma and COPD • High therapeutic ratio when given by inhaled route • Systemic 2 effects when given systemically or at high inhaled doses • High nebulised doses given in acute attack

  13. Muscarinic (cholinergic) receptors • M1-receptors enhance the cholinergic reflex • M2-receptors inhibit acetylcholine release • M3-receptors mediate bronchoconstriction and mucus secretion

  14. BRONCHODILATORS: ANTICHOLINERGICS • Block post junctional end plate M3 receptors • Ipratropium qid , Tiotropium od - inhaled route only - high therapeutic ratio • Used in COPD - less effective in asthma • High nebulised doses of ipratropium used in acute COPD and in acute asthma

  15. BRONCHODILATOR/ANTINFLAMMATORY • :METHYLXANTHINES • Oral (Theophylline) for maintenance therapy • SR formulation useful for nocturnal dips • Used as add to inhaled steroid as complimentary non steroidal anti-inflammatory • IV (Aminophylline) for acute attacks • Non selective phosphodiesterase inhibitor (cAMP) • Adenosine antagonist • Low therapeutic ratio - P450 drug interactions (e.g. erythromycin) • Used in asthma and COPD

  16. Anti-inflammatory :PDE4 inhibitors • Roflumilast –oral tablet od • Indicated for COPD only • Minimal effect on FEV1 • Reduces exacerbations –additive to LABA or LAMA • Adverse effects : Nausea/Diarrhoea/Headache/Weight loss • ? Place in COPD guidelines as add on to ICS/LABA/LAMA

  17. Mucolytics • Oral carbocisteine , erdosteine • To reduce sputum viscosity and aide sputum expectoration [and reduce exacerbations ] in COPD • Rarely used –only as add on to other treatments

  18. TREATMENT OF CHRONIC ASTHMA • AIMS: Abolish sympt, min 2-use, normalise FEV1, reduce PEF variability, reduce exac, prevent long term airway remod • Avoid triggers • Suppress inflammatory cascade with inh steroid • +/- non steroidal anti-inflamm therapy –eg theophylline ,anti-leukotriene ,anti-histamine • Stabilise smooth muscle with LABA –only once optimal anti-inflamm therapy in place

  19. TREATMENT OF ACUTE ASTHMA • Oral prednisolone (or iv hydrocortisone ) • Nebulised high dose salbutamol, ± Neb ipratropium, ± iv aminophylline/magnesium • 60% O2 • ITU Assisted mecahnical intubated ventilation if falling PaO2 and rising PaCO2 • - never use respiratory stimulant

  20. Non-pharmacological intervention: smoking cessation Never smoked or not susceptible to smoke 100 75 50 25 0 Smoked regularly and susceptibleto its effects Stopped at 45 FEV1 (% of value at age 25) Disability Stopped at 65 Death 25 50 75 Age (years) Fletcher et al., 1977

  21. TREATMENT OF STABLE COPD • Prevent FEV1 decline - stop smoking • Treat reversible component • - Inhaled steroid • - Short/Long acting beta-2 agonists - Short/Long acting anticholinergics • -Theophylline • Pulm rehab • Vaccination –influenza/pneumococcal • Domiciliary O2 to prevent cor pulmonale • Venesection for polycythaemia • Lung volume reduction surgery for highly slected patients

  22. TREATMENT OF ACUTE COPD • Nebulised high dose salbutamol + ipratropium • Oral prednisolone • Antibiotic (amoxycillin) if infection • 24-28% O2 • Respiratory stimulant (doxapram) to improve ventilation • Non invasive ventilation instead of doxapram • ITU Intubated assisted ventilation only if reversible component (eg pneumonia)

More Related